WuXi Biologics Statement
SHANGHAI, Feb. 8, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries in Shanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022. We understand that the reason for this action is because U.S. government agencies have not been able to...
Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals
NANJING, China, Feb. 8, 2022 /PRNewswire/ -- Simcere is thrilled to announce Bijoyesh Mookerjee, M.D., as our Chief Medical Officer, Oncology, of Simcere Pharmaceutical Group. Bijoyesh will be responsible for Simcere's oncology clinical pipeline strategy and development, enhancing our global research capability, as well as advancing the company's international development. "Welcome Dr. Bijoyesh Mookerjee to join Simcere...
Singapore-Johor VTL resumes with COVID-19 test results issued by Jebhealth
SINGAPORE, Feb. 8, 2022 /PRNewswire/ -- With the resumption of the land VTL between Singapore and Johor Bahru on Jan 21, about 2,000 travellers are expected to cross the causeway each day, in hope that we can eventually scale up to the normal 300,000 daily commutes. Many would be meeting their loved ones for the first time this year...
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics
Two-year research collaboration to develop new reactive group chemistries targeting non-cysteine amino acids to expand druggable binding sites and identify novel targets in oncology and immunology Collaborators at Scripps are pioneers in the field of chemical biology and chemistry SEONGNAM, South Korea and SAN DIEGO, Calif., Feb. 8, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South...
mRNA COVID-19 Vaccines are Safe for People with Cancer According to New Study in JNCCN
Researchers at Fox Chase Cancer Center conducted the largest published, peer-reviewed, study to-date examining the short-term adverse effects of mRNA COVID-19 vaccination in patients with cancer—finding they experienced no more, and no different, side effects compared to non-cancer patients. PLYMOUTH MEETING, Pa., Feb. 8, 2022 /PRNewswire/ -- New research in the February...
IonOpticks enters OEM partnership with Bruker that sets a new standard for mass spectrometry-based research
MELBOURNE, Australia, Feb. 8, 2022 /PRNewswire/ -- Premium manufacturer of chromatography for proteomics applications, IonOpticks, has entered an OEM partnership with the Bruker Corporation (Nasdaq: BRKR), allowing Bruker to expand their portfolio of 4D-Proteomics solutions with the release of the Bruker Focus Series columns which will leverage the technology of IonOpticks' revolutionary Aurora Series columns. "Bruker is pleased...
Covaris AFA-energetics™ Enables True Automated Total Nucleic Acid Extraction and Purification Workflows from FFPE Tissues
A fully automated, high-throughput deparaffinization and total Nucleic Acids extraction and purification kit for FFPE samples WOBURN, Mass., Feb. 7, 2022 /PRNewswire/ -- Covaris, LLC ("Covaris" or "the Company"), a manufacturer of advanced tools enabling life science innovations, announced the launch of a fully automated, high-throughput deparaffinization and total nucleic acids extraction kit...
US FDA Study May Proceed letter for Clarity’s Cu-64 SAR-bisPSMA trial in prostate cancer
SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has received a confirmation from the US Food and Drug Administration (FDA) that the diagnostic 64Cu SAR-bisPSMA trial (COBRA) may proceed. Clarity's...
KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE
SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the BIO CEO Conference, to be held in person and virtually in New York, NY, from 14-17 February 2022. Hosted annually...
Samsung Biologics receives 2022 CMO Leadership Award in all six categories
INCHEON, South Korea, Feb. 7, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science Leader. Samsung Biologics received a total of six CMO Leadership Awards across all performance categories: capabilities,...
